ECSP19051377A - Derivados de pirrolotriazina como inhibidor de cinasas - Google Patents
Derivados de pirrolotriazina como inhibidor de cinasasInfo
- Publication number
- ECSP19051377A ECSP19051377A ECSENADI201951377A ECDI201951377A ECSP19051377A EC SP19051377 A ECSP19051377 A EC SP19051377A EC SENADI201951377 A ECSENADI201951377 A EC SENADI201951377A EC DI201951377 A ECDI201951377 A EC DI201951377A EC SP19051377 A ECSP19051377 A EC SP19051377A
- Authority
- EC
- Ecuador
- Prior art keywords
- kinase inhibitor
- pyrrolotriazine derivatives
- present
- diseases
- prevention
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la Fórmula Química 1 definido en la presente memoria descriptiva, o una sal farmacéuticamente aceptable del mismo. El compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que se asocian con acciones inhibidoras de cinasas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170034059A KR102398659B1 (ko) | 2017-03-17 | 2017-03-17 | 카이네이즈 저해제로서의 피롤로트리아진 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19051377A true ECSP19051377A (es) | 2019-07-31 |
Family
ID=63522428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201951377A ECSP19051377A (es) | 2017-03-17 | 2019-07-17 | Derivados de pirrolotriazina como inhibidor de cinasas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11084823B2 (es) |
| EP (1) | EP3596081A4 (es) |
| JP (1) | JP6864124B2 (es) |
| KR (2) | KR102398659B1 (es) |
| CN (1) | CN110167943B (es) |
| AU (1) | AU2018236672B2 (es) |
| BR (1) | BR112019015428A2 (es) |
| CA (1) | CA3049648C (es) |
| CL (1) | CL2019002025A1 (es) |
| CO (1) | CO2019007836A2 (es) |
| DO (1) | DOP2019000194A (es) |
| EC (1) | ECSP19051377A (es) |
| IL (1) | IL269144B2 (es) |
| MX (1) | MX394038B (es) |
| MY (1) | MY189983A (es) |
| NZ (1) | NZ755298A (es) |
| PE (1) | PE20191715A1 (es) |
| PH (1) | PH12019502046A1 (es) |
| RU (1) | RU2726632C1 (es) |
| SA (1) | SA519402114B1 (es) |
| SG (1) | SG11201906467VA (es) |
| WO (1) | WO2018169373A1 (es) |
| ZA (1) | ZA201904554B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018235654B2 (en) | 2017-03-17 | 2021-11-18 | Mitsui Chemicals Crop & Life Solutions, Inc. | Plant disease control agent |
| WO2020154350A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100666514B1 (ko) | 1999-05-21 | 2007-02-28 | 브리스톨-마이어즈 스퀴브 컴페니 | 키나제의 피롤로트리아진 저해제 |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EP1957485B1 (en) * | 2005-12-02 | 2013-02-13 | Bayer HealthCare, LLC | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| BRPI0707245A2 (pt) | 2006-01-23 | 2011-04-26 | Crystalgenomics Inc | derivados de imidazopiridina que inibem a atividade de proteìna quinase, método para a preparação destes e composição farmacêutica contendo os mesmos |
| PL2215094T3 (pl) | 2007-11-15 | 2016-09-30 | Związki heterocykliczne zawierające n | |
| AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| ES2573716T3 (es) * | 2010-05-07 | 2016-06-09 | Gilead Connecticut, Inc. | Compuestos de piridona y aza-piridona y métodos de utilización |
| PE20141228A1 (es) | 2011-09-22 | 2014-10-01 | Pfizer | Derivados de pirrolopirimidina y purina |
| US9745320B2 (en) | 2013-01-18 | 2017-08-29 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof |
| US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| CA2924362C (en) | 2013-09-18 | 2018-12-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of btk and/or jak3 kinases |
| CN104974163B (zh) | 2014-04-14 | 2017-11-07 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| CN104829610B (zh) | 2014-06-20 | 2017-03-15 | 中国科学院合肥物质科学研究院 | 一种新型布鲁顿酪氨酸激酶抑制剂 |
| CN105837572B (zh) | 2015-02-02 | 2019-04-19 | 四川大学 | N-取代苯基酰胺衍生物及其制备方法和用途 |
| CN105646497B (zh) * | 2016-02-01 | 2019-06-04 | 南京格亚医药科技有限公司 | 吡咯并三嗪酮衍生物 |
| CN106432249B (zh) * | 2016-09-30 | 2018-12-04 | 陕西科技大学 | 一类吡咯并[2，1-f][1，2，4]三嗪母核化合物的合成及其医药用途 |
-
2017
- 2017-03-17 KR KR1020170034059A patent/KR102398659B1/ko active Active
-
2018
- 2018-03-19 CN CN201880006529.0A patent/CN110167943B/zh active Active
- 2018-03-19 RU RU2019123998A patent/RU2726632C1/ru active
- 2018-03-19 WO PCT/KR2018/003140 patent/WO2018169373A1/en not_active Ceased
- 2018-03-19 AU AU2018236672A patent/AU2018236672B2/en active Active
- 2018-03-19 CA CA3049648A patent/CA3049648C/en active Active
- 2018-03-19 MY MYPI2019004124A patent/MY189983A/en unknown
- 2018-03-19 MX MX2019010595A patent/MX394038B/es unknown
- 2018-03-19 NZ NZ755298A patent/NZ755298A/en unknown
- 2018-03-19 BR BR112019015428-0A patent/BR112019015428A2/pt not_active Application Discontinuation
- 2018-03-19 US US16/478,920 patent/US11084823B2/en active Active
- 2018-03-19 PE PE2019001453A patent/PE20191715A1/es unknown
- 2018-03-19 JP JP2019571195A patent/JP6864124B2/ja active Active
- 2018-03-19 EP EP18766994.0A patent/EP3596081A4/en active Pending
- 2018-03-19 SG SG11201906467VA patent/SG11201906467VA/en unknown
-
2019
- 2019-07-08 SA SA519402114A patent/SA519402114B1/ar unknown
- 2019-07-11 ZA ZA2019/04554A patent/ZA201904554B/en unknown
- 2019-07-17 EC ECSENADI201951377A patent/ECSP19051377A/es unknown
- 2019-07-19 CL CL2019002025A patent/CL2019002025A1/es unknown
- 2019-07-22 CO CONC2019/0007836A patent/CO2019007836A2/es unknown
- 2019-07-24 DO DO2019000194A patent/DOP2019000194A/es unknown
- 2019-09-05 IL IL269144A patent/IL269144B2/en unknown
- 2019-09-09 PH PH12019502046A patent/PH12019502046A1/en unknown
-
2022
- 2022-04-18 KR KR1020220047811A patent/KR102428882B1/ko active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000112A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
| ECSP18093777A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| CO2020007156A2 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| PE20151654A1 (es) | Inhibidores de cdc7 | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |